Journal of Autoimmunity · 2023 · 17 citations · 51 references
Life SciencesImmunologyMolecular BiologyAutoimmunityInnate ImmunitySignal TransductionB Cell BiologyB-cell ResponsesInnate Immune ResponseInnate Immune Signaling PathwaysInterferon ResponsesSystemic Lupus ErythematosusAutoreactive B Cell ActivationAutoreactive B Cell ResponsesB-cell PathogenesisNf-κb SignalingNuclear Factor Kappa B ModulationNuclear Factor Kappa B SignalingRegulation By E3 Ubiquitin LigasesType I Interferon Signature
Both TLR7 and NF-κB hyperactivity are known to contribute to pathogenesis in Systemic Lupus Erythematosus (SLE), driving a pro-interferon response, autoreactive B cell expansion and autoantibody production. UBE2L3 is an SLE susceptibility gene which drives plasmablast/plasma cell expansion in SLE, but its role in TLR7 signalling has not been elucidated. We aimed to investigate the role of UBE2L3 in TLR7-mediated NF-κB activation, and the effect of UBE2L3 inhibition by Dimethyl Fumarate (DMF) on SLE B cell differentiation in vitro. Our data demonstrate that UBE2L3 is critical for activation of NF-κB downstream of TLR7 stimulation, via interaction with LUBAC. DMF, which directly inhibits UBE2L3, significantly inhibited TLR7-induced NF-κB activation, differentiation of memory B cells and plasmablasts, and autoantibody secretion in SLE. DMF also downregulated interferon signature genes and plasma cell transcriptional programmes. These results demonstrate that UBE2L3 inhibition could potentially be used as a therapy in SLE through repurposing of DMF, thus preventing TLR7-driven autoreactive B cell maturation.
51
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text
James Bentham, David Morris, Deborah S. Cunninghame Graham et al. · Nature Genetics · 2015 · 1.1K citations · Full text
Life Sciences, Genetics, Immunology +17